The Value and Sustainability of Ocrelizumab in Relapsing Multiple Sclerosis: A Cost-Effectiveness and Budget Impact Analysis. (2019). Farmeconomia. Health Economics and Therapeutic Pathways, 20(1). https://doi.org/10.7175/fe.v20i1.1435